Ann: Morgans Initiates Research Coverage, page-9

Agreed. The lag you mention is at least in part caused by the risk they mention in the report:
"RAP has not yet secured the relevant regulatory clearance to enable its ResAppDX® system to be properly commercialised. There can be no certainty that these clearances and approvals will be obtained. This is the main risk to our valuation and price target. Therefore an investment in RAP is only suitable for investors with a higher risk profile."
As well, there is a hesitance to jump in pre 14th July (ie Friday).
There would be those who are waiting for FDA and will buy in at whatever they can get it for then (50 to 60c?) when it is almost fully de-risked........assuming it will readily commercialise, which Morgans believe will inevitably follow.
IMO